Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.

Completed · Phase 1

Conditions studied: Rheumatoid Arthritis, Healthy Volunteers

In brief

The purpose of this study is to investigate the drug interaction between fostamatinib and rifampicin by comparing the safety, tolerability and plasma concentration of fostamatinib when administered alone and with rifampicin in healthy subjects

Key facts

Study ID

NCT01336218

Run by

AstraZeneca

People needed

15

Starts

2011-04-01

Expected to finish

2011-07-01

Last updated by the study team

2011-07-22

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Provision of informed consent prior to any study specific procedures
• Males or females aged 18 to 55 years (inclusive)
• Minimum weight of 50 kg and a body mass index (BMI) of 18 to 35 kg/m2 (inclusive)
• Female subjects must have a negative pregnancy test at screening and admission of each treatment period, must not be lactating, and must be of non-childbearing potential

You may not qualify if…

• History or presence of gastrointestinal, hepatic or renal disease (except for cholecystectomy)
• Any clinically significant illness, medical or surgical procedure, or trauma within 4 weeks before Period 1 Day 1
• Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day
• Absolute neutrophil count of less than 2500/mm3 or 2.5 x 109/L
• Any previous treatment with fostamatinib

Where it is running

• Research Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.